This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Frequency Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Frequency Therapeutics şirketinin toplam hissedar öz sermayesi $36.7M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $46.3M ve $9.6M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$41.72m
Eşitlik	US$36.74m
Toplam yükümlülükler	US$9.61m
Toplam varlıklar	US$46.35m

Son finansal sağlık güncellemeleri

Analiz Makalesi • Jan 01

Is Frequency Therapeutics (NASDAQ:FREQ) Weighed On By Its Debt Load?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Analiz Makalesi • Jan 19

Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Analiz Makalesi • Jul 31

Health Check: How Prudently Does Frequency Therapeutics (NASDAQ:FREQ) Use Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Analiz Makalesi • Mar 15

We're Not Worried About Frequency Therapeutics' (NASDAQ:FREQ) Cash Burn

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Frequency...

Recent updates

Analiz Makalesi • Jan 01

Is Frequency Therapeutics (NASDAQ:FREQ) Weighed On By Its Debt Load?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Analiz Makalesi • Jan 19

Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Analiz Makalesi • Aug 18

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are Reducing Their Forecasts For This Year

Market forces rained on the parade of Frequency Therapeutics, Inc. ( NASDAQ:FREQ ) shareholders today, when the...

Analiz Makalesi • Jul 31

Health Check: How Prudently Does Frequency Therapeutics (NASDAQ:FREQ) Use Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Analiz Makalesi • Apr 04

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are More Bearish Than They Used To Be

Today is shaping up negative for Frequency Therapeutics, Inc. ( NASDAQ:FREQ ) shareholders, with the analysts...

Analiz Makalesi • Mar 15

We're Not Worried About Frequency Therapeutics' (NASDAQ:FREQ) Cash Burn

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Frequency...

Analiz Makalesi • Jan 22

If You Had Bought Frequency Therapeutics (NASDAQ:FREQ) Shares A Year Ago You'd Have Earned 55% Returns

If you want to compound wealth in the stock market, you can do so by buying an index fund. But one can do better than...

Analiz Makalesi • Dec 27

Have Insiders Sold Frequency Therapeutics, Inc. (NASDAQ:FREQ) Shares Recently?

Some Frequency Therapeutics, Inc. ( NASDAQ:FREQ ) shareholders may be a little concerned to see that the Independent...

Analiz Makalesi • Dec 10

How Much Are Frequency Therapeutics, Inc. (NASDAQ:FREQ) Insiders Taking Off The Table?

It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...

Analiz Makalesi • Nov 19

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Frequency Therapeutics, Inc. (NASDAQ:FREQ) investors will be delighted, with the company turning in some strong...

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: FREQ 'nin kısa vadeli varlıkları ( $42.5M ) kısa vadeli yükümlülüklerini ( $9.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: FREQ un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: FREQ borçsuzdur.

Borcun Azaltılması: FREQ un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: FREQ şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: FREQ un, serbest nakit akışı her yıl % 30.3 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2023/11/05 20:37
Gün Sonu Hisse Fiyatı	2023/11/03 00:00
Kazançlar	2023/09/30
Yıllık Kazançlar	2022/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Frequency Therapeutics, Inc. 7 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Jack Allen	Baird
Mayank Mamtani	B. Riley Securities, Inc.
Daniil Gataulin	Chardan Capital Markets, LLC

This company is no longer active

Frequency Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Frequency Therapeutics (NASDAQ:FREQ) Weighed On By Its Debt Load?

Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry?

Health Check: How Prudently Does Frequency Therapeutics (NASDAQ:FREQ) Use Debt?

We're Not Worried About Frequency Therapeutics' (NASDAQ:FREQ) Cash Burn

Recent updates

Korro Bio, Inc. completed the acquisition of Frequency Therapeutics, Inc. (NasdaqGS:FREQ) from a group of shareholders.

New major risk - Market cap size

Insufficient new directors

New major risk - Financial position

Frequency Therapeutics, Inc. Announces the Resignation of Christopher Loose as Chief Scientific Officer

New major risk - Share price stability

Korro Bio, Inc. entered into a definitive merger agreement to acquire Frequency Therapeutics, Inc. (NasdaqGS:FREQ) from a group of shareholders in a reverse merger transaction.

Frequency Therapeutics, Inc. Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

Is Frequency Therapeutics (NASDAQ:FREQ) Weighed On By Its Debt Load?

Frequency Therapeutics, Inc. Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss

Price target decreased to US$6.67

Frequency Therapeutics, Inc. Completes Enrollment of Phase 2B Study of FX-322 for the Treatment of Sensorineural Hearing Loss

Frequency Therapeutics, Inc.(NasdaqGS:FREQ) dropped from Russell 2500 Index

Consensus forecasts updated

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Frequency Therapeutics, Inc., Annual General Meeting, Jun 21, 2022

Price target decreased to US$12.00

Insufficient new directors

Frequency Therapeutics, Inc. Announces Peter P. Pfreundschuh Stepping Down as Chief Financial Officer

Price target increased to US$14.33

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry?

Insufficient new directors

Frequency Therapeutics, Inc. Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise

Frequency Therapeutics, Inc. Announces New FX-322 Results Showing that Additional Study Participants Gain Hearing Improvements at Later Time Points

Price target decreased to US$12.75

Consensus revenue estimates fall to US$36.2m

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are Reducing Their Forecasts For This Year

Second quarter 2021 earnings released: US$0.52 loss per share (vs US$0.19 loss in 2Q 2020)

Health Check: How Prudently Does Frequency Therapeutics (NASDAQ:FREQ) Use Debt?

Lieff Cabraser Heimann & Bernstein, LLP Announces That Class Action Litigation Has Been Filed Against Frequency Therapeutics, Inc

Frequency Therapeutics, Inc.(NasdaqGS:FREQ) dropped from Russell 2500 Growth Index

Co-Founder exercised options to buy US$1.1m worth of stock.

Rosen Law Firm Encourages Frequency Therapeutics, Inc. Investors with Losses Exceeding $100,000 to Secure Counsel Before Important Deadline

Price target decreased to US$14.25

Consensus forecasts updated

Forecast to breakeven in 2025

Insider recently bought US$89k worth of stock

Consensus forecasts updated

First quarter 2021 earnings released: US$0.60 loss per share (vs US$0.16 loss in 1Q 2020)

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are More Bearish Than They Used To Be

Full year 2020 earnings released: US$0.82 loss per share (vs US$2.29 loss in FY 2019)

Independent Director exercised options to buy US$316k worth of stock.

We're Not Worried About Frequency Therapeutics' (NASDAQ:FREQ) Cash Burn

Co-­Founder exercised options and sold US$469k worth of stock

Frequency Therapeutics, Inc. Announces Publication of Phase 1/2 Data Showing Hearing Improvements in Acquired Sensorineural Hearing Loss Patients Receiving FX-322

New 90-day high: US$54.87

Frequency Therapeutics, Inc. Appoints Kevin Franck as Senior Vice President of Strategic Marketing and New Product Planning

Co-­Founder exercised options and sold US$385k worth of stock

New 90-day high: US$40.50

If You Had Bought Frequency Therapeutics (NASDAQ:FREQ) Shares A Year Ago You'd Have Earned 55% Returns

Frequency Therapeutics Appoints Quentin McCubbin, Ph.D., as Chief Manufacturing Officer

Co-­Founder exercised options and sold US$594k worth of stock

Have Insiders Sold Frequency Therapeutics, Inc. (NASDAQ:FREQ) Shares Recently?

Independent Director recently sold US$1.7m worth of stock

Frequency Therapeutics, Inc. Enters into an Agreement for Termination of Lease and Voluntary Surrender of Premises

Price target raised to US$36.33

Co-­Founder exercised options and sold US$437k worth of stock

How Much Are Frequency Therapeutics, Inc. (NASDAQ:FREQ) Insiders Taking Off The Table?

New 90-day high: US$28.86

Frequency Therapeutics Appoints Peter Pfreundschuh as Chief Financial Officer

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Third quarter 2020 earnings released: US$0.16 loss per share

Revenue beats expectations, earnings disappoint

Co­-Founder & Chief Scientific Officer notifies of intention to sell stock

New 90-day high: US$25.05

Frequency Therapeutics Appoints Cynthia Feldmann to Its Board of Directors

Frequency Therapeutics, Inc. Completes Enrollment of FX-322 Phase 2a Study for Sensorineural Hearing Loss

New 90-day high: US$24.96

Frequency Therapeutics, Inc. announced that it has received $42.301944 million in funding from a group of investors

Co-Founder exercised options and sold US$469k worth of stock

Co-Founder exercised options and sold US$385k worth of stock

Co-Founder exercised options and sold US$594k worth of stock

Co-Founder exercised options and sold US$437k worth of stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock